Antiva Biosciences, Inc.

Antiva Biosciences, Inc. company information, Employees & Contact Information

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.

Company Details

Employees
26
Address
6000 Shoreline Ct, South San Francisco,california 94080,united States
Phone
(650)822-1400
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Antiva Biosciences, Inc. employee's phone or email?

Antiva Biosciences, Inc. Questions

News

Antiva Biosciences Announces Positive Top-Line Results from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk Human Papillomavirus (hrHPV) Infection - PR Newswire

Antiva Biosciences Announces Positive Top-Line Results from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk Human Papillomavirus (hrHPV) Infection PR Newswire

Antiva Biosciences Strengthens Leadership with Key New Appointments - PR Newswire

Antiva Biosciences Strengthens Leadership with Key New Appointments PR Newswire

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO - PR Newswire

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO PR Newswire

Antiva Biosciences Closes $31 Million Series D Equity Financing - PR Newswire

Antiva Biosciences Closes $31 Million Series D Equity Financing PR Newswire

Top Antiva Biosciences, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant